Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 6/20 | 0.52 |
| ▸ | MMP8 | P22894 | 5/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959930 | 1.00 | FKBP1A (0.52) | FKBP1AMMP8MMP3MMP12MMP13 | |
| SCHEMBL3256303 | 0.86 | FKBP1A (0.56) | FKBP1AMMP8MMP3MMP12MMP13 | |
| SCHEMBL3256301 | 0.86 | FKBP1A (0.56) | FKBP1AMMP8MMP3MMP12MMP13 | |
| SCHEMBL6830973 | 0.85 | FKBP1A (0.58) | FKBP1AMMP8MMP3MMP12MMP13 | |
| SCHEMBL6830972 | 0.85 | FKBP1A (0.58) | FKBP1AMMP8MMP3MMP12MMP13 | |
| SCHEMBL26212073 | 0.81 | FKBP1A (0.51) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6831374 | 0.81 | FKBP1A (0.54) | FKBP1AMMP8MMP3MMP12MMP13 | |
| SCHEMBL6831371 | 0.81 | FKBP1A (0.54) | FKBP1AMMP8MMP3MMP12MMP13 | |
| Hydroxyamine SCHEMBL5894442 | 0.79 | FKBP1A (0.50) | FKBP1AMMP8MMP3MMP12MMP13 | |
| SCHEMBL10815653 | 0.78 | FKBP1A (0.48) | FKBP1AMMP8MMP3MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
| US-7030051-B2 | Dirhodium catalyst compositions and methods for using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-04-18 | — | — | US | disclosed |
| US-6962891-B2 | Solid support dirhodium catalyst compositions and methods for making and using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030130112-A1 | Solid support dirhodium catalyst compositions and methods for making and using same | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-07-10 | — | — | US | disclosed |
| US-20030130536-A1 | Dirhodium catalyst compositions and methods for using same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130112-A1 | Solid support dirhodium catalyst compositions and methods for making and using same | DOHH, DHODH, HDHD5 | FKBP1A 1837/4885MMP8 3332/4885MMP3 4249/4885 |
| US-20030130536-A1 | Dirhodium catalyst compositions and methods for using same | DOHH, DNPH1, NOTUM | FKBP1A 2687/4885MMP8 2948/4885MMP3 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.